Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Embria Studies FDA Expectations Before Successful EpiCor NDI

This article was originally published in The Tan Sheet

Executive Summary

FDA’s formal acknowledgment of Embria’s NDI notification for EpiCor comes after the firm called FDA early in the process to discuss the pending notification and worked to understand the agency’s expectations fully. Kevin Boot, Embria’s regulatory counsel, recommends simple notifications that are “readable by everyone.”

You may also be interested in...

FDA “Undercuts” NDI Guidance Opposition With Compliance Cost Estimate – CRN

OMB approves FDA’s estimate as the official measure for the supplement industry’s anticipated burden in complying with the NDI notification regulation.

In Brief

Dr. Reddy’s launches Allegra-D equivalent

FDA Defends Estimate For NDI Notification Preparation

Supplement firms already should have compiled the information for a new dietary ingredient notification when they substantiated the safety of the ingredient, FDA says.

Related Content


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts